{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:43:04Z","timestamp":1793619784606,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jacl.2025.10.066","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:32:28Z","timestamp":1761186748000},"page":"66-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4435-1235","authenticated-orcid":false,"given":"Arturo","family":"Cesaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Acerbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Scialla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Porcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Panico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Argenziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrio","family":"Iaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2703-4232","authenticated-orcid":false,"given":"Maria Grazia","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1609-4684","authenticated-orcid":false,"given":"Vincenzo","family":"De Sio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6943-278X","authenticated-orcid":false,"given":"Felice","family":"Gragnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0141-0127","authenticated-orcid":false,"given":"Michele","family":"Golino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Ruscica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Carugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5018-830X","authenticated-orcid":false,"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.10.066_bib0001","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacl.2025.10.066_bib0002","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jacl.2025.10.066_bib0003","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2025.10.066_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100701","article-title":"Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond","volume":"19","author":"Safarova","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.10.066_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1415668","article-title":"Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis","volume":"11","author":"Jiang","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacl.2025.10.066_bib0006","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2023.01.001","article-title":"Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT)","volume":"366","author":"Gargiulo","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.10.066_bib0007","first-page":"4","article-title":"Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk","author":"Cesaro","year":"2019","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2025.10.066_bib0008","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2459\/JCM.0000000000000611","article-title":"Adherence to proprotein convertase subtilisin\/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience","volume":"19","author":"Gragnano","year":"2018","journal-title":"J Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.jacl.2025.10.066_bib0009","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.3390\/nu14122450","article-title":"Lipid variability and risk of cardiovascular diseases and all-cause mortality: a systematic review and meta-analysis of cohort studies","volume":"14","author":"Li","year":"2022","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.jacl.2025.10.066_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027639","article-title":"Variability in lipid levels and risk for cardiovascular disease: an electronic health record-based population cohort study","volume":"12","author":"Manemann","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"15","key":"10.1016\/j.jacl.2025.10.066_bib0011","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jacc.2015.02.017","article-title":"Visit-to-Visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes","volume":"65","author":"Bangalore","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacl.2025.10.066_bib0012","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.123.016842","article-title":"Variability in lipid profiles during young adulthood and the risk of coronary artery calcium incidence in midlife: insights from the CARDIA study","volume":"17","author":"Gao","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"issue":"19","key":"10.1016\/j.jacl.2025.10.066_bib0013","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.3390\/jcm12196231","article-title":"LDL cholesterol variability impacts the prognosis of patients with chronic ischemic heart disease: a real-world Italian experience","volume":"12","author":"Faggiano","year":"2023","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.jacl.2025.10.066_bib0014","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.amjmed.2022.06.018","article-title":"Inter-individual variability in lipid response: a narrative review","volume":"135","author":"Patnaik","year":"2022","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2025.10.066_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108812","article-title":"Therapeutic PCSK9 targeting: inside versus outside the hepatocyte?","volume":"268","author":"Corsini","year":"2025","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jacl.2025.10.066_bib0016","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/ehjcvp\/pvw006","article-title":"Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER","volume":"2","author":"Karlson","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"21","key":"10.1016\/j.jacl.2025.10.066_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026550","article-title":"Real-world effectiveness of PCSK9 inhibitors in reducing LDL-C in patients with familial hypercholesterolemia in Italy: A retrospective cohort study based on the AIFA monitoring registries","volume":"12","author":"Arca","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.jacl.2025.10.066_bib0018","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00392-023-02247-8","article-title":"High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany","volume":"112","author":"Makhmudova","year":"2023","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2025.10.066_bib0019","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamacardio.2018.4178","article-title":"Interindividual variation in low-density lipoprotein cholesterol level reduction with evolocumab: an analysis of FOURIER trial data","volume":"4","author":"Qamar","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"39","key":"10.1016\/j.jacl.2025.10.066_bib0020","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1093\/eurheartj\/ehae576","article-title":"Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry","volume":"45","author":"Schubert","year":"2024","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jacl.2025.10.066_bib0021","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10557-020-07137-z","article-title":"LDL cholesterol reduction variability with different types and doses of statins in monotherapy or combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry","volume":"36","author":"Climent","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"10.1016\/j.jacl.2025.10.066_bib0022","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.atherosclerosis.2015.03.004","article-title":"Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients","volume":"240","author":"Descamps","year":"2015","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.jacl.2025.10.066_bib0023","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.amjcard.2013.01.297","article-title":"A pilot study identifying statin nonadherence with visit-to-visit variability of low-density lipoprotein cholesterol","volume":"111","author":"Mann","year":"2013","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2025.10.066_bib0024","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s00392-023-02257-6","article-title":"Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany","volume":"113","author":"Koenig","year":"2024","journal-title":"Clinical Research in Cardiology"},{"issue":"5","key":"10.1016\/j.jacl.2025.10.066_bib0025","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2024.10.106","article-title":"Real-world efficacy and safety of inclisiran: a single-country, multicenter, observational study (CHOLINET Registry)","volume":"85","author":"Gargiulo","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2025.10.066_bib0026","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jacl.2016.11.005","article-title":"Variability in low density lipoprotein-cholesterol concentrations after alirocumab injection","volume":"11","author":"Elfar","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"9965","key":"10.1016\/j.jacl.2025.10.066_bib0027","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.jacl.2025.10.066_bib0028","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jacl.2019.10.004","article-title":"Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses","volume":"13","author":"Robinson","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.jacl.2025.10.066_bib0029","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc Res"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425004866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425004866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:45:44Z","timestamp":1791373544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425004866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1933287425004866"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.10.066","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.10.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}